Insider Transactions Reported by 21 Insiders of Elicio Therapeutics, Inc.

Symbol
ELTX on Nasdaq
Location
Boston, MA

There are no Buy or Sell transactions made by insiders since 11 Mar 2025

Elicio Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Yekaterina Chudnovsky Director, 10%+ Owner $39,452,192 03 Jun 2025
EISA-ABC LLC 10%+ Owner $15,925,082 31 Aug 2021
Itzhak Goldberg Director $9,807,199 01 Jul 2022
Robert Connelly CEO, President and Director, Director $959,737 02 Feb 2026
Christopher Haqq Executive Vice President, Head of R&D and Chief Medical Officer $456,752 02 Feb 2026
Jay R. Venkatesan Director $251,306 19 May 2025
Preetam Shah Chief Strategy and Financial Officer $191,040 02 Feb 2026
Peter DeMuth Chief Scientific Officer $171,482 02 Feb 2026
VICTOR F. GANZI Director $87,150 09 Jun 2022
GILBERT S. OMENN Director $87,150 09 Jun 2022
John F. Neylan Executive Vice President, Chief Medical Officer and Head of Research 02 Mar 2022
Gregory S. Curhan Chief Financial Officer 02 Mar 2022
Jennifer J. Rhodes Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary 02 Mar 2022
Annette Matthies Chief Business Officer 01 Jun 2023
Assaf Segal Director 01 Jun 2023
KAREN J. WILSON Director 19 May 2025
Allen Nissenson Director 19 May 2025
Julian Adams Director 19 May 2025
Carol Gail Ashe Director 19 May 2025
ROBERT R. RUFFOLO Director 19 May 2025
Brian Piekos Chief Financial Officer 01 Feb 2024

Recent Insider Transactions by Companies or Individuals for Elicio Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.